PDCD1 and head and neck cancer: Immune checkpoint inhibitors such as the Programmed cell Death protein 1 (PD-1) inhibitors, nivolumab, and pembrolizumab, have emerged as a promising approach in the treatment of various malignancies, including head and neck cancer [1, 2].